Home > Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - March 2012 (Table of Contents)

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - March 2012

GlobalData
March 27, 2012
68 Pages - SKU: GBDT3824130

Abstract Table of Contents Search inside this report Related Reports

1 Table of contents: 1.1 List of Tables; 1.2 List of Figures
2 Pharmaceuticals & Healthcare, Global, Deal Summary: 2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, February 2012; 2.2 Pharmaceuticals & Healthcare, Global, Top Deals, February 2012; 2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Values, February 2012
3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type: 3.1 Pharmaceuticals & Healthcare, Global, M&A, February 2012; 3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, February 2012; 3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, February 2012; 3.4 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, February 2012
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2012: 4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2012; 4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, September 2011 - February 2012; 4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 2012; 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2011 - February 2012; 4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Values (US$ m), September 2011 - February 2012; 4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2011 - February 2012
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2012: 5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2012; 5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2012; 5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), September 2011 - February 2012; 5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2011 - February 2012; 5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2011 - February 2012; 5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2011 - February 2012
6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area: 6.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, February 2012; 6.2 Pharmaceuticals & Healthcare, Global, Oncology Deals, February 2012; 6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, February 2012; 6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, February 2012; 6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, February 2012; 6.6 Pharmaceuticals & Healthcare, Global, Respiratory, Deals, February 2012; 6.7 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, February 2012
7 Deal Summary by Geography: 7.1 Pharmaceuticals & Healthcare, North America Deals, February 2012; 7.2 Pharmaceuticals & Healthcare, Europe, Deals, February 2012; 7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, February 2012; 7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, February 2012
8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors: 8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, September 2011 - February 2012; 8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2011 - February 2012
9 Further Information: 9.1 Methodology; 9.2 About GlobalData; 9.3 Contact Us; 9.4 Disclosure information; 9.5 Disclaimer
1.1 List of Tables: Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 2: Pharmaceuticals & Healthcare, Global, Top Deals, February 2012; Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), February 2012; Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, February 2012; Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2011 - February 2012; Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, February 2012; Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 10: Pharmaceuticals & Healthcare, Global, Debt Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 11: Pharmaceuticals & Healthcare, Global, Top Debt Offering Deals, February 2012; Table 12: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal values (US$ m), September 2011 - February 2012; Table 13: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 14: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, February 2012; Table 15: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, September 2011 - February 2012; Table 16: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), February 2012; Table 17: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 18: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2011 - February 2012; Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 21: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2011 - February 2012; Table 22: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), February 2012; Table 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2011 - February 2012; Table 24: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2011 - February 2012; Table 25: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), September 2011 - February 2012; Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), September 2011 - February 2012; Table 28: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Deal Value, February 2012; Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, February 2012; Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, February 2012; Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal values (US$ m), September 2011 - February 2012; Table 32: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), February 2012; Table 33: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2011 - February 2012; Table 34: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 2012; Table 35: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 36: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 37: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 38: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 39: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 40: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 41: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 42: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 43: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 44: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 45: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 46: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Table 47: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2011 - February 2012
1.2 List of Figures: Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Values (%),February 2012; Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 4: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2011 - February 2012; Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 7: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 8: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 9: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 10: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2011 - February 2012; Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%) and Deal Values (%), February 2012; Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2011 - February 2012; Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2011 - February 2012; Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2011 - February 2012; Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2011 - February 2012; Figure 19: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2011 - February 2012; Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2011 - February 2012; Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), February 2012; Figure 25: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 26: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 27: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 28: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 29: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 30: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 31: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 32: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 33: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 34: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 35: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 36: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2011 - February 2012; Figure 37: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2011 - February 2012

Research assistance

We can help you find what you need. Call us or write us:

US: 800.298.5699

Int'l: +1.240.747.3093

Need help in your search?

Related Markets

Pharmaceuticals Company Reports

Share this report

Email a colleague

Other tasks

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!